IP Library Granted Patent US 9,724,315
Granted Patent B2
US 9,724,315 · App. 13/328,369 · Granted Aug 8, 2017

Compounded transdermal pain management

Inventors: Jay Richard Ray, II (Conroe, TX); Charles D. Hodge (Conroe, TX)
Assignee: CMPD Licensing, LLC
A61K31/135A61K9/0014A61K9/06A61K31/167A61K31/192A61K31/195A61K31/197A61K31/4168A61K47/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,724,315
App. No.
13/328,369
Granted
Aug 8, 2017
Kind
B2
Abstract

The present embodiments relate to topically delivered medication (compounded) for treatment of pain, inflammation, muscle fatigue, spasms, and/or other ailments. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include a salt load of approximately 30% or greater. The transdermal cream may include a unique base composition such that the transdermal cream may be able to remain stable and avoid degradation for six months or more and capable of effective delivery of active ingredient concentrations exceeding approximately 40% or more of the total formulation weight. The active ingredients may include a nerve depressant, NSAID, muscle relaxant, opiate agonist, local anesthetic, NMDA receptor antagonist, and a tricyclic antidepressant. In one embodiment, the transdermal cream may comprise ketamine HCL, gabapentin, clonidine HCL and baclofen. The transdermal cream may deliver an enhanced topical delivery flux of ketamine via a single transdermal application.

Claims (8)

1. A compounded transdermal pain management cream for topical administration of multiple medications simultaneously, the compounded transdermal pain management cream comprising:

several medications within a base composition for topical administration to a patient, the several medications including

at least one nerve depressant; at least one NSAID (Non-Steroidal Anti-Inflammatory Drug);

at least one muscle relaxant;

at least one opioid or opiate agonist;

at least one local anesthetic, wherein the at least one local anesthetic is in an amount between approximately 1.0% and approximately 5% of the transdermal cream by weight; and at least one NMDA (N-Methyl-D-aspartate) receptor antagonist comprising ketamine in an amount of 30% to 40% of the transdermal cream by weight, and

at least one tricyclic antidepressant,

wherein the several medications comprise approximately 40% or more of the transdermal cream by weight.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2014
From: JCDS HOLDINGS, LLC
To: CMPD LICENSING, LLC
Reel/Frame 033795/0393 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2011
From: RAY, JAY RICHARD, II; HODGE, CHARLES D.
To: JCDS HOLDINGS, LLC
Reel/Frame 027399/0589 →
Continuity (3)
Continuation PCTUS2011054324 · Sep 30, 2011
Provisional Application 61541716 · Sep 30, 2011
Related Publication 20130085171A1 · Apr 4, 2013